title: New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps.
abstract: 2013 saw few therapeutic innovations that really benefitted patients; once again, marketing authorisations were too often granted despite inadequate clinical data. The French health authorities implemented a few measures designed to protect patients from dangerous drugs, including market withdrawals, restrictions on use, and delisting.
mesh_terms: D017277:Drug Approval; D016527:Drug Costs; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D005602:France; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D056737:Safety-Based Drug Withdrawals; D013997:Time Factors